UK Trade & Investment (UKTI) and the Association of Biotech Led Enterprise (ABLE) have jointly announced signing a memorandum of understanding (MoU) to encourage and develop collaborative opportunities between Indian Life Sciences organisations and the United Kingdom, in Bangalore. This MoU is expected to become a milestone for the UK Oncology Mission, which was on a tri-city tour (Mumbai, Bangalore and Chennai).
Dr P. M. Murali, President, ABLE, said, ABLE is pleased to be signing an MOU with UKTI for collaborating on a range of opportunities, one of which is happening today. Cancer represents one of the most challenging disease areas that require researchers and clinicians to work together at a global level. We recognize the importance of this delegation and appreciate its purpose.
The MoU will aim at combining UK’s heritage and leadership in the area of healthcare and Life Sciences and India’s emerging and thriving healthcare ecosystem to promote and develop the Life Sciences sector in both countries. The partnership will include the participation of UK and Indian experts in Life Sciences in the areas of industry, research and trade. It will further promote UK and India as each other’s partner of choice in Life Sciences such as drug discovery, bioinformatics, regenerative medicine, clinical research, agri-bio, oncology and regulation.
UKTI and ABLE will also encourage trade in the sector between the two countries through registration from healthcare companies basis their interests and capabilities. By exploring partnerships and business opportunities, UKTI will enable Indian healthcare players to rapidly expand their businesses globally.
Image Gallery
